PMID- 12973372
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20031023
LR  - 20191107
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 35
IP  - 10
DP  - 1999 Oct
TI  - Pantoprazole: a new proton pump inhibitor in the management of upper 
      gastrointestinal disease.
PG  - 773-808
AB  - Pantoprazole, the third proton pump inhibitor (PPI) to become available, has been 
      extensively investigated. Pantoprazole inhibits acid more powerfully than 
      histamine H(2) receptor antagonists (H(2)RAs) and omperazole 20 mg and raises 
      median 24-h gastric pH from about 1.5 to 3-4 in healthy volunteers and in 
      duodenal ulcer patients to above 5. Results from studies have confirmed that 
      pantoprazole is superior to H(2)RAs in speed of healing and symptom relief in 
      patients with peptic ulcer. In patients with duodenal ulcer pantoprazole was as 
      effective as omperazole 20 mg and in patients with gastric ulcer pantoprazole was 
      statistically superior to omeprazole 20 mg after 4 weeks. In triple combination 
      therapy of peptic ulcer disease, the mean eradication rate of Helicobacter pylori 
      in data pooled from 32 pantoprazole-based studies was 86% and compliance with 
      treatment was about 90%. Results pooled from 5 large clinical trials of 
      gastroesophageal reflux disease showed healing rates significantly superior to 
      those achieved with H(2)RAs and similar to those of other PPIs at 4 and 8 weeks. 
      Symptom relief was more rapid with pantoprazole and maintenance treatment kept 
      the majority of patients in remission; relapse rates at 1 year were 25-28% on 20 
      mg daily and 6-22% on 40 mg daily. Maintenance treatment with pantoprazole 40 mg 
      has been shown to keep most patients with aggressive or refractory ulcer and 
      reflux disease in remission for up to 3 years. Pantoprazole was also effective in 
      the management of patients with Zollinger-Ellison syndrome. In volunteers given 
      aspirin, pantoprazole 40 mg proved significantly superior to ranitidine and 
      placebo in preventing the development of mucosal damage and was significantly 
      better than placebo in preventing gastric ulcer and duodenal ulcer in arthritic 
      patients on nonsteroidal antiinflammatory drugs. Clinical trials, postmarketing 
      surveillance and long-term studies have confirmed that pantoprazole is effective 
      and safe for the short- and long-term management of peptic ulcer and reflux 
      disease, with side effects similar in incidence and type to those of H(2)RAs.
CI  - (c) 1999 Prous Science. All rights reserved.
FAU - Bardhan, K D
AU  - Bardhan KD
AD  - Rotherham General Hospitals NHS Trust, Rotherham, UK.
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
EDAT- 2003/09/16 05:00
MHDA- 2003/09/16 05:01
CRDT- 2003/09/16 05:00
PHST- 2003/09/16 05:00 [pubmed]
PHST- 2003/09/16 05:01 [medline]
PHST- 2003/09/16 05:00 [entrez]
AID - 561696 [pii]
AID - 10.1358/dot.1999.35.10.561696 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 1999 Oct;35(10):773-808. doi: 10.1358/dot.1999.35.10.561696.